True lab orchestration isn't about coordinating instruments, it's about connecting scientific intent, data, and decisions ...

In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, explains why the full ...

In today's ACT Brief, we examine genuine patient partnership in trial design, how AI enables informed recruitment while ...

In today's ACT Brief, we examine why black-box AI fails in clinical trials, how participant understanding drives engagement ...

In this Q&A, John Worden, chief commercial officer at Javara, discusses why clinical trial recruitment has remained stubbornly one-size-fits-all, how AI can identify patients at scale without ...

In this Q&A, Patrick Mizer, chief technology officer at Ledger Run, discusses how payment reliability has become a ...

In this video interview, Sylviane de Viron of CluePoints and Abigail Dirks of Tufts CSDD discuss what the RBQM financial ...

Senior leaders reiterated that GCP expectations are geography-agnostic, and inadequate inspection access can render foreign ...

Across both participant-centered research and broader industry data, a consistent theme emerges: engagement is not a request for novelty. It is a request for less friction. Participants are asking for ...

In today's ACT Brief, we examine value hidden in the RBQM financial model, why rare disease research leads on genuine patient ...

Beyond Compliance: NetraMark's Joseph Geraci, PhD, on Making AI-Driven Patient Subgroups Explainable ...

In this episode of Beyond Compliance, Otis Johnson, PhD, MPA, founder and principal consultant at Vantix Operations, speaks with Joseph Geraci, PhD, co-founder and chief scientific and technical ...